John Freund Biography and Net Worth

Director of SI-BONE


John G. Freund, M.D. has served as a member of our board of directors since January 2013. Dr. Freund founded Skyline Ventures, a venture capital firm, in October 1997 and has served as a Managing Director of Skyline since then. Prior to joining Skyline, Dr. Freund served as Managing Director in the private equity group of Chancellor Capital Management, a private capital investment firm. In November 1995, Dr. Freund co-founded Intuitive Surgical, Inc., a medical device company, and served on its board of directors until March 2000. From 1988 to 1994, he held various positions at Acuson Corporation, a maker of ultrasound equipment that is now part of Siemens, most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a general partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988, Dr. Freund was at Morgan Stanley & Co., an investment banking company, where he co-founded the Healthcare Group in the Corporate Finance Department in 1983. Dr. Freund has served on the board of directors of Collegium Pharmaceuticals, Inc., a biotechnology company, since 2014, Tetraphase Pharmaceuticals, Inc. since 2012, and Sutro Biopharma, Inc., a biotechnology company, since 2014. Dr. Freund also serves on the board of directors of six U.S. registered investment funds managed by affiliates of the Capital Group, Inc. He also previously served on the board of directors of five publicly traded companies, Map Pharmaceuticals, Inc., a biopharmaceutical company, MAKO Surgical Corp., a medical device company, Proteon Therapeutics, Inc., a biotechnology company, Concert Pharmaceuticals, Inc., a biopharmaceutical company and was Chairman of XenoPort, Inc., a biopharmaceutical company. Dr. Freund is a member of the Advisory Board for the Harvard Business School of Healthcare Initiative. Dr. Freund received a B.A. in History from Harvard College, an M.D. from Harvard Medical School, and an M.B.A. from Harvard Business School, where he was a Baker Scholar.

What is John Gordon Freund's net worth?

The estimated net worth of John Gordon Freund is at least $1.38 million as of August 9th, 2023. Dr. Freund owns 103,899 shares of SI-BONE stock worth more than $1,376,662 as of December 22nd. This net worth evaluation does not reflect any other assets that Dr. Freund may own. Learn More about John Gordon Freund's net worth.

How do I contact John Gordon Freund?

The corporate mailing address for Dr. Freund and other SI-BONE executives is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. SI-BONE can also be reached via phone at (408) 207-0700 and via email at [email protected]. Learn More on John Gordon Freund's contact information.

Has John Gordon Freund been buying or selling shares of SI-BONE?

John Gordon Freund has not been actively trading shares of SI-BONE in the last ninety days. Most recently, John Gordon Freund sold 30,000 shares of the business's stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $20.54, for a transaction totalling $616,200.00. Following the completion of the sale, the director now directly owns 103,899 shares of the company's stock, valued at $2,134,085.46. Learn More on John Gordon Freund's trading history.

Who are SI-BONE's active insiders?

SI-BONE's insider roster includes Jeffrey Dunn (Director), Laura Francis (CEO), John Freund (Director), Jeryl Hilleman (Director), Gregory Hinckley (Director), Michael Pisetsky (SVP), and Anthony Recupero (Insider). Learn More on SI-BONE's active insiders.

Are insiders buying or selling shares of SI-BONE?

In the last year, insiders at the sold shares 26 times. They sold a total of 80,217 shares worth more than $1,217,756.36. The most recent insider tranaction occured on November, 18th when Director Jeffrey W Dunn sold 1,609 shares worth more than $19,999.87. Insiders at SI-BONE own 3.9% of the company. Learn More about insider trades at SI-BONE.

Information on this page was last updated on 11/18/2024.

John Gordon Freund Insider Trading History at SI-BONE

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/9/2023Sell30,000$20.54$616,200.00103,899View SEC Filing Icon  
6/14/2021Sell17,990$31.28$562,727.20View SEC Filing Icon  
5/26/2021Sell17,138$31.85$545,845.30View SEC Filing Icon  
5/24/2021Sell51,027$32.54$1,660,418.58View SEC Filing Icon  
3/17/2021Sell666,200$30.39$20,245,818.00View SEC Filing Icon  
3/15/2021Sell235,887$31.13$7,343,162.31View SEC Filing Icon  
3/11/2021Sell63,928$31.05$1,984,964.40View SEC Filing Icon  
12/2/2020Sell100,000$23.28$2,328,000.00View SEC Filing Icon  
10/19/2020Sell190,053$22.00$4,181,166.00View SEC Filing Icon  
See Full Table

John Gordon Freund Buying and Selling Activity at SI-BONE

This chart shows John Gordon Freund's buying and selling at SI-BONE by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

SI-BONE Company Overview

SI-BONE logo
SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Read More

Today's Range

Now: $13.25
Low: $12.76
High: $13.37

50 Day Range

MA: $13.42
Low: $12.15
High: $16.05

2 Week Range

Now: $13.25
Low: $11.70
High: $21.70

Volume

496,538 shs

Average Volume

383,329 shs

Market Capitalization

$555.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2